MAP2K7 and neuroblastoma: Conversely, loss of YAP sensitizes neuroblastoma cells to trametinib, implying that combinatorial inhibition of MEK and YAP signaling could be a therapeutic strategy for neuroblastoma patients with hyperactivated MAPK signaling.